PharmGen Science

팜젠사이언스 · 004720

Health Care Pharmaceuticals · KOSPI

Small-cap

Market cap US$50.6M (₩69.8B)

Overview

PharmGen Science makes prescription medicines, including digestive-system treatments, as well as over-the-counter drugs and obesity treatments, and supplies health-functional foods and beauty products to consumers.

Its products reach patients and end-users through prescription channels and general retail. Listed on KOSPI, Korea's main stock exchange, the company operates three distinct segments: pharmaceuticals, healthcare (functional foods and beauty), and property rental income from a building it owns in Seoul.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$125.4M

▲ +1.0% YoY

Operating profit · FY2025

US$4.3M

▼ −43.8% YoY

Net income · FY2025

−US$84.5M

Turned to loss

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$120.9M(₩166.8B)	US$124.1M(₩171.3B)	US$125.4M(₩173.1B)
Operating profit	US$6.6M(₩9.1B)	US$7.7M(₩10.6B)	US$4.3M(₩6B)
Net income	US$4.1M(₩5.7B)	US$2M(₩2.8B)	−US$84.5M(−₩116.6B)

Revenue

FY2023US$120.9M
FY2024US$124.1M
FY2025US$125.4M

Operating profit

FY2023US$6.6M
FY2024US$7.7M
FY2025US$4.3M

Net income

FY2023US$4.1M
FY2024US$2M
FY2025−US$84.5M

Key ratios (FY2025)

ROE

-79.7%

Debt/Eq

33.6%

Op. margin

3.5%

Net margin

-67.4%

Rev. YoY

▲ +1.0%

Why it matters

The company owns and operates its own building, the PharmGen Science Building in Seoul's Bangbae-dong district, generating rental income as a secondary business alongside its core pharmaceutical operations.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?